Sponsor Pipeline

Umoja Biopharma Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
1
Recruiting
6
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-30 NCT07735533 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies Phase 1/2 Not Yet Recruiting
2026-07-30 NCT07735546 A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07735533 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies Lymphoma, B Cell Not Yet Recruiting
Phase 1
NCT06528301 A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+… Lymphoma, B-Cell Recruiting
NCT07735546 A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma Multiple Myeloma in Relapse Not Yet Recruiting
Disease Areas
DLBCL (2) Leukemia (1) Chronic Lymphocytic Leukemia (CLL) (1) Non-Hodgkin Lymphoma (1) Follicular Lymphoma (1) Multiple Myeloma (1)
Get alerts when Umoja Biopharma's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free